Explore the Agenda
8:00 am Registration & Light Breakfast
8:50 am Chair’s Opening Remarks
Showcasing Clinical Evidence Across Melanoma & Emerging Solid Tumor Indication to Inform Where TILs Can Deliver Meaningful Benefit to Patients
9:00 am Advancing TIL Clinical Development by Generating Early Efficacy Signals in Cold Solid Tumors
- Demonstrating initial clinical feasibility of TIL therapy in colorectal and prostate cancer
- Exploring patient selection and tumor sourcing challenges in low immunogenic indications
- Translating early treatment experience into future trial design decisions
9:30 am Advancing TIL Therapy in Advanced Melanoma With Clinical Evidence Supporting a Next Generation Treatment Approach
- Presenting pivotal clinical data from patients with advanced melanoma, demonstrating achievement of the study’s primary endpoint and supporting the potential for the first marketed TIL therapy in China
- Exploring innovations in treatment delivery through an IL-2-free regimen, low-intensity pretreatment, and a feeder-free manufacturing process designed to simplify therapy while maintaining clinical efficacy
- Examining outcomes in predominantly acral and mucosal melanoma populations and discussing what these findings could mean for the future evolution of TIL therapy
10:00 am Morning Break & Speed Networking
Join our dedicated networking session to engage in dynamic, fast-paced conversations with fellow industry professionals, exchange insights and expertise, and expand your network within the rapidly evolving TIL therapies landscape. This interactive session will help you foster impactful partnerships and advance innovation across the field.
Engineering Better TIL Products Through Targeted Tumor-Reactive Cell Selection
11:00 am Expanding TIL Clinical Activity Beyond Melanoma by Selectively Enriching Tumor Reactive T-cells
- Demonstrating clinical feasibility of isolating tumor reactive T-cells across multiple solid tumor types
- Sharing early phase safety and response observations from a selective TIL approach
- Informing future trial design by linking cell composition to clinical outcomes
11:30 am Automated GMP Manufacturing of γδ-Enriched Tumor-Reactive T Cells using CliniMACS Prodigy: Enabling Decentralized Cell Therapy Production for AML Relapse Prevention
- Generation of tumor-reactive T-cell products from healthy donors and AML patients
- Composition, characterization and functionality of tumor-reactive T-cell products
- Implications for clinical translation and future development
12:00 pm Advancing TIL Therapy Through Neoantigen-Guided Selection of Tumor- Reactive T-Cells
- Leveraging patient-specific neoantigens to identify and enrich functional tumorreactive T-cells
- Overcoming low frequencies of tumor-reactive lymphocytes in non-melanoma solid tumors
- Establishing a framework for next-generation, precision TIL manufacturing
12:30 pm Lunch & Networking
Advancing Gene-Edited TIL Therapies to Enhance Persistence, Overcome Tumor Resistance & Drive More Durable Clinical Responses
1:30 pm Strengthening Solid Tumor Efficacy by Engineering TILs With Precision Genome Editing to Improve Recognition & Durability
- Integrating targeted genetic edits to enhance tumor-specific antigen recognition
- Reducing functional exhaustion to support sustained TIL persistence after infusion
- Evaluating how multiplex engineering impacts response durability in solid tumors
2:00 pm SMART G-Rex® & SensoRexTM Technology for In-line, Non-Invasive, and Real-Time Monitoring of TIL Expansion
- SMART G-Rex® and SensoRex™ enable in-line, non-invasive monitoring of TIL growth and culture health
- TIL Pre-REP results suggest that sensor thresholds can identify fast-growing cultures ready for earlier harvest at target cell yields
- TIL REP monitoring could guide harvest before growth plateaus while meeting celldose targets, with potential benefits for post-thaw proliferation
2:30 pm Panel Discussion: Reducing Development Risk by Evaluating Genetic Editing Strategies Shaping the Future of TIL Therapies
- Comparing genome editing approaches used to enhance potency, persistence, and tumor recognition
- Reviewing safety, manufacturability, and regulatory trade-offs of engineered TIL designs
- Identifying where genetic modification adds clear clinical value vs. added complexity
- Can TIL manufacturing be designed for in vivo development rather than culturing the cells in vitro?
3:00 pm Not All TILs Are Created Equal
3:30 pm Afternoon Break & Poster Session
Contribute to the conversation by sharing your latest research and innovations with the global cell therapy community and leading experts advancing the future of TIL therapies.
Managing Scientific & Process Complexity to Improve Reliability & Decision Making in TIL Manufacturing
4:30 pm Building Robust Manufacturing & Quality Systems to Enable the Commercialization of TIL Therapies
- Establishing CMC quality systems that support consistent TIL manufacturing from early development through commercialization
- Exploring lessons learned from scaling autologous cell therapies from research to industrial manufacturing while maintaining product quality and regulatory compliance
- Navigating global regulatory expectations and integrating manufacturing, quality, and clinical development strategies to accelerate TIL therapy approval and commercialization
5:00 pm Balancing Process Flexibility & Standardization While Preserving Antigen Specificity
- Optimizing manufacturing processes to increase cell dose and scalability while maintaining antigen specificity, functionality, and product quality throughout clinical development
- Ensuring product comparability as manufacturing processes evolve from early clinical studies to larger trials without compromising the biological characteristics that drive therapeutic activity
- Reducing regulatory and scale-up risk by establishing robust, reproducible manufacturing strategies that support both clinical expansion and future commercial readiness